Claims for Patent: 7,462,349

Summary for Patent: 7,462,349

Title:	Beta interferon for the treatment of chronic spinal cord injury
Abstract:	The invention is intended to adapt an already established clinical procedure for the treatment of multiple sclerosis (MS)--the use of beta interferon--to treat chronic human spinal cord injury. The present invention relates to the prevention of chronic inflammation and demyelination following spinal cord injury.
Inventor(s):	Kalderon; Nurit (New York, NY)
Assignee:
Application Number:	10/693,042
Patent Claims:	1. A method for treating the secondary damage resulting from spinal cord injury, which comprises administering to a subject in need thereof a therapeutically effective amount of beta interferon or an analogue thereof. 2. The method as recited in claim 1, wherein the beta interferon or analogue thereof is commercially available and is approved by the FDA for the treatment of multiple sclerosis (MS). 3. The method as recited in claim 2, wherein the beta interferon or analogue thereof is administered as prescribed for the treatment of MS. 4. The method as recited in claim 1, wherein the beta interferon or analogue thereof is Betaseron, Avonex, Rebif or Cinnovex. 5. The method as recited in any one of claims 2-4, wherein the commercially available beta interferon is administered at the dosage and frequency as prescribed for the treatment of relapsing-remitting MS. 6. The method as recited in claim 5, wherein the beta interferon is administered starting at about the 11th day or later after injury. 7. The method as recited in claim 5, wherein the beta interferon is administered starting at the 4th week or later after injury. 8. A method of attenuating the progressive chronic inflammation and demyelination resulting from spinal cord injury, which comprises administering to a subject in need thereof a therapeutically effective amount of beta interferon or an analogue thereof. 9. The method as recited in claim 8, wherein the beta interferon or analogue thereof is commercially available and is approved by the FDA for the treatment of MS. 10. The method as recited in claim 9, wherein the beta interferon or analogue thereof is administered as prescribed for the treatment of MS. 11. The method as recited in claim 8, wherein the beta interferon or analogue thereof is Betaseron, Avonex, Rebif or Cinnovex. 12. The method as recited in any one of claims 9-11, wherein the commercially available beta interferon is administered at the dosage and frequency as prescribed for the treatment of relapsing-remitting MS. 13. The method as recited in claim 12, wherein the beta interferon is administered starting at about the 11th day or later after injury. 14. The method as recited in claim 12, wherein the beta interferon is administered starting at the 4th week or later after injury. 15. A method for therapy and rescue of the uninjured neuronal fiber tracts in chronic spinal cord injuries, which comprises administering to a subject in need thereof a therapeutically effective amount of beta interferon or an analogue thereof. 16. The method as recited in claim 15, wherein the beta interferon or analogue thereof is commercially available and is approved by the FDA for the treatment of MS. 17. The method as recited in claim 16, wherein the beta interferon or analogue thereof is administered as prescribed for the treatment of MS. 18. The method as recited in claim 15, wherein the beta interferon or analogue thereof is Betaseron, Avonex, Rebif or Cinnovex. 19. The method as recited in any one of claims 16-18, wherein the commercially available beta interferon is administered at the dosage and frequency as prescribed for the treatment of relapsing-remitting MS. 20. The method as recited in claim 19, wherein the beta interferon is administered starting at about the 11th day or later after injury. 21. The method as recited in claim 19, wherein the beta interferon is administered starting at the 4th week or later after injury. 22. A method for repair and rescue of the neurologic function of the uninjured neuronal fiber tracts in chronic spinal cord injuries, which comprises administering to a subject in need thereof a therapeutically effective amount of beta interferon or an analogue thereof. 23. The method as recited in claim 22, wherein the beta interferon or analogue thereof is commercially available and is approved by the FDA for the treatment of MS. 24. The method as recited in claim 23, wherein the beta interferon or analogue thereof is administered as prescribed for the treatment of MS. 25. The method as recited in claim 22, wherein the beta interferon or analogue thereof is Betaseron, Avonex, Rebif or Cinnovex. 26. The method as recited in any one of claims 23-25, wherein the commercially available beta interferon is administered at the dosage and frequency as prescribed for the treatment of relapsing-remitting MS. 27. The method as recited in claim 26, wherein the beta interferon is administered starting at about the 11th day or later after injury. 28. The method as recited in claim 26, wherein the beta interferon is administered starting at the 4th week or later after injury.

Details for Patent 7,462,349

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bayer Healthcare Pharmaceuticals Inc.	BETASERON	interferon beta-1b	For Injection	103471	07/23/1993		2022-10-24
Biogen Inc.	AVONEX	interferon beta-1a	For Injection	103628	05/17/1996		2022-10-24
Biogen Inc.	AVONEX	interferon beta-1a	Injection	103628	05/28/2003		2022-10-24
Biogen Inc.	AVONEX	interferon beta-1a	Injection	103628	02/27/2012		2022-10-24